Second Sight Medical Products Stock Forecast, Price & News

Second Sight Medical Products' stock was trading at $3.53 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, EYES shares have decreased by 75.2% and is now trading at $0.8761.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Second Sight Medical Products in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Second Sight Medical Products.

Second Sight Medical Products is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for Second Sight Medical Products.

Second Sight Medical Products Inc (NASDAQ:EYES) announced its earnings results on Thursday, August, 13th. The medical device company reported ($0.15) earnings per share (EPS) for the quarter. Second Sight Medical Products had a negative net margin of 994.14% and a negative return on equity of 470.66%.
View Second Sight Medical Products' earnings history.

2 brokers have issued 1-year price objectives for Second Sight Medical Products' shares. Their forecasts range from $2.00 to $2.50. On average, they anticipate Second Sight Medical Products' share price to reach $2.25 in the next year. This suggests a possible upside of 156.8% from the stock's current price.
View analysts' price targets for Second Sight Medical Products.

Second Sight Medical Products saw a increase in short interest in August. As of August 31st, there was short interest totaling 611,900 shares, an increase of 18.6% from the August 15th total of 516,000 shares. Based on an average daily trading volume, of 560,800 shares, the short-interest ratio is presently 1.1 days. Approximately 4.9% of the shares of the company are short sold.
View Second Sight Medical Products' Short Interest.

Some companies that are related to Second Sight Medical Products include electroCore (ECOR), Fc Global Realty (FCRE), Reshape Lifesciences (RSLS), IRIDEX (IRIX), Helius Medical Technologies (HSDT), Helius Medical Technologies (HSDT), ENDRA Life Sciences (NDRA), CHF Solutions (CHFS), Precision Optics (PEYE), Digirad (DRAD), Viveve Medical (VIVE), Micron Solutions (MICR), Guided Therapeutics (GTHP), Vaso (VASO) and Non-Invasive Monitoring Systems (NIMU).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Second Sight Medical Products investors own include Zynerba Pharmaceuticals (ZYNE), Adaptimmune Therapeutics (ADAP), Cara Therapeutics (CARA), Shopify (SHOP), VBI Vaccines (VBIV), Canopy Growth (CGC), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Ekso Bionics (EKSO) and OrganiGram (OGI).

(EYES) raised $32 million in an initial public offering (IPO) on Wednesday, November 19th 2014. The company issued 3,500,000 shares at a price of $9.00 per share. MDB Capital Group, LLC served as the underwriter for the IPO.

Second Sight Medical Products trades on the NASDAQ under the ticker symbol "EYES."

Second Sight Medical Products' stock is owned by a variety of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.23%). Company insiders that own Second Sight Medical Products stock include Edward David Randolph, Gregg Williams, Jonathan Will Mcguire and Stephen D Okland.
View institutional ownership trends for Second Sight Medical Products.

EYES stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Second Sight Medical Products.

Shares of EYES can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of EYES stock can currently be purchased for approximately $0.88.

Second Sight Medical Products has a market capitalization of $20.25 million and generates $3.38 million in revenue each year. The medical device company earns $-33,590,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. Second Sight Medical Products employs 123 workers across the globe.

The official website for Second Sight Medical Products is www.secondsight.com.

Second Sight Medical Products' mailing address is 12744 SAN FERNANDO ROAD SUITE 400, SYLMAR CA, 91342. The medical device company can be reached via phone at 818-833-5000 or via email at [email protected]